The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review

[1]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[2]  C. Foster,et al.  Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. , 2016, Pharmacology & therapeutics.

[3]  G. Poropat,et al.  Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options , 2015, Drug design, development and therapy.

[4]  M. Koplay,et al.  Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. , 2015, World journal of hepatology.

[5]  H. Inui,et al.  Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. , 2015, World journal of gastroenterology.

[6]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[7]  S. Gitto,et al.  Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future , 2015, Gastroenterology research and practice.

[8]  Y. Chawla,et al.  Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. , 2015, Journal of clinical and experimental hepatology.

[9]  Simone Moreira de Macêdo,et al.  The role of renin-angiotensin system modulation on treatment and prevention of liver diseases , 2014, Peptides.

[10]  B. Baran,et al.  Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? , 2014, World journal of gastroenterology.

[11]  S. Santos,et al.  Angiotensin 1–7: A peptide for preventing and treating metabolic syndrome , 2014, Peptides.

[12]  D. Brenner,et al.  Interactions between the intestinal microbiome and liver diseases. , 2014, Gastroenterology.

[13]  R. Santos,et al.  Alamandine: a new member of the angiotensin family , 2014, Current opinion in nephrology and hypertension.

[14]  F. Vogt,et al.  Chronic blockade of angiotensin AT1 receptors improves cardinal symptoms of metabolic syndrome in diet‐induced obesity in rats , 2014, British journal of pharmacology.

[15]  S. Santos,et al.  The therapeutic role of Renin-Angiotensin System blockers in obesity- related renal disorders. , 2014, Current clinical pharmacology.

[16]  L. Henry,et al.  Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets , 2014, Alimentary pharmacology & therapeutics.

[17]  F. Mach,et al.  Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[18]  J. D. Feltenberger,et al.  Oral Formulation of Angiotensin-(1–7) Improves Lipid Metabolism and Prevents High-Fat Diet–Induced Hepatic Steatosis and Inflammation in Mice , 2013, Hypertension.

[19]  T. Hoffmann,et al.  Inhibition of Glutaminyl Cyclases alleviates CCL2‐mediated inflammation of non‐alcoholic fatty liver disease in mice , 2013, International journal of experimental pathology.

[20]  Y. Makino,et al.  Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis , 2013, Journal of Gastroenterology.

[21]  A. Ferreira,et al.  Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. , 2013, The Journal of endocrinology.

[22]  P. Paschos,et al.  Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. , 2012, World journal of hepatology.

[23]  K. Nakajima.  Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease , 2012, International journal of hepatology.

[24]  S. Santos,et al.  Exercise induces renin–angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice , 2012, Peptides.

[25]  Y. Wen,et al.  Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats , 2012, Acta Pharmacologica Sinica.

[26]  S. Santos,et al.  Increased circulating angiotensin-(1–7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet , 2012, Regulatory Peptides.

[27]  S. Santos,et al.  Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7) , 2012, Peptides.

[28]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[29]  O. Jöhren,et al.  Double blockade of angiotensin II (AT1)‐receptors and ACE does not improve weight gain and glucose homeostasis better than single‐drug treatments in obese rats , 2012, British journal of pharmacology.

[30]  L. Cassis,et al.  The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. , 2012, American journal of physiology. Heart and circulatory physiology.

[31]  N. Kalupahana,et al.  The renin‐angiotensin system: a link between obesity, inflammation and insulin resistance , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[32]  S. Santos,et al.  Angiotensin-(1–7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes , 2012, Peptides.

[33]  K. Wahbi,et al.  Meta-Analysis of Renin-Angiotensin-Aldosterone Blockade for Heart Failure in Presence of Preserved Left Ventricular Function , 2011, Journal of cardiovascular pharmacology and therapeutics.

[34]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[35]  J. Fujimoto,et al.  Toll‐like receptor signaling in liver regeneration, fibrosis and carcinogenesis , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[36]  L. Aparicio,et al.  Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. , 2011, Reviews on recent clinical trials.

[37]  James E. Nelson,et al.  Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease , 2011, Hepatology.

[38]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[39]  S. Friedman,et al.  Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis , 2010, Fibrogenesis & tissue repair.

[40]  R. Morishita,et al.  Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. , 2010, International journal of molecular medicine.

[41]  D. Leroith,et al.  Insulin resistance in obesity as the underlying cause for the metabolic syndrome. , 2010, The Mount Sinai journal of medicine, New York.

[42]  C. Mandarim-de-Lacerda,et al.  Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. , 2010, Clinical science.

[43]  Josef M. Penninger,et al.  Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters , 2010, Pharmacology & Therapeutics.

[44]  N. Takahashi,et al.  The renin angiotensin system and the metabolic syndrome. , 2010, The open hypertension journal.

[45]  S. Santos,et al.  Improved Lipid and Glucose Metabolism in Transgenic Rats With Increased Circulating Angiotensin-(1-7) , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[46]  T. Kusakabe,et al.  Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice , 2010, Diabetologia.

[47]  S. Sookoian,et al.  Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. , 2009, Atherosclerosis.

[48]  Y. Nakayama,et al.  Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[49]  F. Albayrak,et al.  Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes? , 2009, European journal of pharmacology.

[50]  M. Teixeira,et al.  Renin-angiotensin system in the pathogenesis of liver fibrosis. , 2009, World journal of gastroenterology.

[51]  M. Iwai,et al.  Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis , 2009, Hypertension Research.

[52]  H. Yoshiji,et al.  Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat , 2009, BMC Research Notes.

[53]  L. Mogoantă,et al.  Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. , 2009, World journal of gastroenterology.

[54]  J. Sowers,et al.  Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. , 2008, Journal of hepatology.

[55]  F. Fyhrquist,et al.  Renin‐angiotensin system revisited , 2008, Journal of internal medicine.

[56]  A. Ferreira,et al.  Recent advances in the angiotensin‐converting enzyme 2–angiotensin(1–7)–Mas axis , 2008, Experimental physiology.

[57]  R. Pedrinelli,et al.  Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. , 2008, Atherosclerosis.

[58]  U. Kintscher,et al.  Liver-Specific Peroxisome Proliferator–Activated Receptor α Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan , 2008, Diabetes.

[59]  L. Cassis,et al.  Local adipose tissue renin-angiotensin system , 2008, Current hypertension reports.

[60]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[61]  R. Carey,et al.  Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure , 2008, Trends in Endocrinology & Metabolism.

[62]  Zhong-tao Zhang,et al.  Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. , 2008, Chinese medical journal.

[63]  O. Jöhren,et al.  Gene expression of mineralocorticoid and glucocorticoid receptors in the limbic system is related to type-2 like diabetes in leptin-resistant rats , 2007, Brain Research.

[64]  M. Başkol,et al.  Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. , 2007, Clinical biochemistry.

[65]  T. Saibara,et al.  Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis , 2007, Hepatology.

[66]  K. Tamura,et al.  The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function , 2007, Current hypertension reports.

[67]  P. Ernsberger,et al.  Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect? , 2007 .

[68]  A. Ferreira,et al.  Angiotensin-(1–7) and the renin–angiotensin system , 2007, Current opinion in nephrology and hypertension.

[69]  J. Sowers,et al.  Angiotensin II-induced NADPH Oxidase Activation Impairs Insulin Signaling in Skeletal Muscle Cells* , 2006, Journal of Biological Chemistry.

[70]  R. Santos,et al.  Circulating Renin Angiotensin System in Childhood Chronic Renal Failure: Marked Increase of Angiotensin-(1–7) in End-Stage Renal Disease , 2006, Pediatric Research.

[71]  Nathan R. Qi,et al.  Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis , 2006, Hypertension.

[72]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[73]  H. Pershadsingh.  Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. , 2006, The international journal of biochemistry & cell biology.

[74]  A. McCullough.  Pathophysiology of nonalcoholic steatohepatitis. , 2006, Journal of clinical gastroenterology.

[75]  U. Kintscher,et al.  Regulation of Peroxisome Proliferator–Activated Receptor &ggr; Activity by Losartan Metabolites , 2006, Hypertension.

[76]  R. Ross,et al.  Visceral Fat Is an Independent Predictor of All‐cause Mortality in Men , 2006, Obesity.

[77]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[78]  Y. Tokusashi,et al.  Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. , 2006, World journal of gastroenterology.

[79]  U. Kintscher,et al.  PPAR&ggr;-Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin , 2005 .

[80]  G. Rosano,et al.  Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome , 2005 .

[81]  K. Chayama,et al.  Angiotensin II Participates in Hepatic Inflammation and Fibrosis through MCP-1 Expression , 2005, Digestive Diseases and Sciences.

[82]  R. Carey,et al.  The renin–angiotensin–aldosterone system, glucose metabolism and diabetes , 2005, Trends in Endocrinology & Metabolism.

[83]  R. A. Santos,et al.  Cardiovascular actions of angiotensin-(1-7). , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[84]  T. Kurtz.  Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator , 2005, Acta Diabetologica.

[85]  N. Ozaki,et al.  Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. , 2005, Diabetes care.

[86]  T. Kurtz,et al.  Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system , 2004, Journal of hypertension.

[87]  Y. Tokusashi,et al.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis , 2004, Hepatology.

[88]  M. Marrero,et al.  Angiotensin II–Induced Insulin Resistance and Protein Tyrosine Phosphatases , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[89]  D. Randall,et al.  Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[90]  A. Quyyumi,et al.  Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome , 2004, Circulation.

[91]  R. Iliescu,et al.  Expression of an angiotensin-( 1 – 7 )-producing fusion protein produces cardioprotective effects in rats , 2004 .

[92]  U. Kintscher,et al.  Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity , 2004, Circulation.

[93]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[94]  K. Chayama,et al.  AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). , 2003, Biochemical and biophysical research communications.

[95]  Thomas Walther,et al.  Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[96]  D. Campbell,et al.  The renin-angiotensin and the kallikrein-kinin systems. , 2003, The international journal of biochemistry & cell biology.

[97]  P. Ghenev,et al.  Adipobiology of disease: adipokines and adipokine-targeted pharmacology. , 2003, Current pharmaceutical design.

[98]  K.,et al.  Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. , 2002, Kidney international.

[99]  S. Umemura,et al.  Angiotensin(1–7) potentiates bradykinin-induced vasodilatation in man , 2001, Journal of hypertension.

[100]  P. Angus,et al.  Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. , 2001, Journal of hepatology.

[101]  W. Rascher,et al.  AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[102]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[103]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[104]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[105]  Ji-lin Cheng,et al.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). , 2000, World journal of gastroenterology.

[106]  S. Umemura,et al.  Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. , 2000, Hypertension.

[107]  L. Lins,et al.  Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension , 1999 .

[108]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[109]  G. Aguilera,et al.  Increased Expression of Type 1 Angiotensin II Receptors in the Hypothalamic Paraventricular Nucleus following Stress and Glucocorticoid Administration , 1995, Journal of neuroendocrinology.

[110]  R. Alexander,et al.  Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.

[111]  Shahinul Alam,et al.  Effect of Telmisartan on Histological Activity and Fibrosis of Non-alcoholic Steatohepatitis: A 1-Year Randomized Control Trial , 2016, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[112]  平田 匠.  Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease : fatty liver protection trial by telmisartan or losartan study (FANTASY) , 2014 .

[113]  I. Herichová,et al.  Renin-angiotensin system: upgrade of recent knowledge and perspectives. , 2013, Endocrine regulations.

[114]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[115]  K. Kotoh,et al.  Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. , 2008, International journal of molecular medicine.

[116]  P. Ernsberger,et al.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? , 2007, Current opinion in pharmacology.

[117]  R. Schwabe,et al.  TLR4 enhances TGF-beta signaling and hepatic fibrosis. , 2007, Nature medicine.

[118]  Y. Ichikawa.  Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. , 2007, Internal medicine.

[119]  C. Stefanadis,et al.  Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. , 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[120]  M. Sasamata,et al.  Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. , 2005, International journal of clinical pharmacology research.

[121]  U. Kintscher,et al.  PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. , 2005, Hypertension.

[122]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[123]  L. Lins,et al.  Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. , 1999, Journal of hypertension.

[124]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.